Busilong Pharmaceuticals: It is expected that the net profit in 2025 will be between 320 million and 468 million yuan.

Boehringer Ingelheim announced that it is expected to achieve a net profit attributable to the owners of the parent company of approximately 320 million to 468 million yuan in the annual year of 2025. Compared with the same period last year, a net profit is expected to turn from a loss to a profit. The net profit attributable to the owners of the parent company in the same period last year was -554 million yuan.